3.17
3.17 (-0.07%)
As of Aug 31, 2021
Cleveland Biolabs Inc [CBLI]
Source:
Company Overview
We are a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Prior to the closing of the Merger (as defined below), we focused exclusively on developing novel approaches to modulate the immune system.
| Country | United States |
| Headquarters | fort collins, colorado |
| Phone Number | (888) 613-8802 |
| Industry | manufacturing |
| CEO | Michael Handley |
| Website | staterabiopharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.7 |
| Operating Profit | $-1.5 |
| Net Income | $-3.4 |
| Net Cash | $-6.3 |
Profit Ratios
| Gross Margin | $0.5 |
| Operating Margin | -230.6 |
| Profit as % of Revenues | 74.7% |
| Profit as % of Assets | -19.8% |
| Profit as % of Stockholder Equity | 33% |
Management Effectiveness
| Return on Equity | 33% |
| Return on Assets | -26.3% |
| Turnover Ratio | 0% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $12.7 |
| Total Liabilities | $22.9 |
| Operating Cash Flow | $-4.7 |
| Investing Cash Flow | $-0 |
| Financing Cash Flow | $-1.7 |
